Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Femasys Inc. FEMY

Healthcare  —  Medical Instruments & Supplies
2.48 0.05 2.06% as of 25 Sep
Market cap
$20.4M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Femasys Inc. (FEMY) Business Profile

Updated before January 2025

Company Overview

Femasys Inc. (NASDAQ: FEMY) is a medical technology company dedicated to transforming women’s healthcare through innovative, non-surgical, and cost-effective solutions. Founded in 2004 and headquartered in Suwanee, Georgia, Femasys focuses on addressing unmet needs in the areas of infertility, contraception, and cancer diagnosis. The company was established by Kathy Lee-Sepsick, who also serves as its President and Chief Executive Officer. Under her leadership, Femasys has grown into a pioneering organization that combines cutting-edge technology with a patient-centric approach to healthcare.

Femasys operates with a mission to provide accessible and effective solutions for women worldwide. The company’s leadership team includes experienced professionals with expertise in medical technology, regulatory affairs, and commercialization strategies. This strong leadership foundation has enabled Femasys to maintain its position as an innovator in the women’s health sector.

Core Business Segments

Femasys Inc. focuses on three primary business segments: infertility treatment, permanent contraception, and cancer diagnostics. Each segment is supported by proprietary technologies and products designed to improve patient outcomes and reduce healthcare costs.

Infertility Treatment

Femasys offers innovative solutions for infertility treatment, including its flagship product, FemaSeed. FemaSeed is a localized directional insemination device designed to deliver sperm directly to the fallopian tube, increasing the chances of conception. This non-surgical and cost-effective alternative to traditional in-vitro fertilization (IVF) provides a more accessible option for couples struggling with infertility.

Permanent Contraception

The company’s FemBloc system is a groundbreaking approach to permanent contraception. FemBloc is a non-surgical, in-office procedure that uses biopolymer technology to block the fallopian tubes, providing a safe and effective alternative to tubal ligation. This innovative solution eliminates the need for invasive surgery, reducing recovery time and associated risks.

Cancer Diagnostics

Femasys is also advancing cancer diagnostics with its FemCerv product, a proprietary endocervical tissue sampler. FemCerv is designed to improve the accuracy of cervical cancer diagnosis by collecting high-quality tissue samples in a minimally invasive manner. This product aligns with the company’s commitment to early detection and prevention of life-threatening conditions.

Business Model

Femasys operates on a business model that integrates product innovation, clinical validation, and strategic partnerships. The company generates revenue through the sale of its proprietary devices and related services. By focusing on non-surgical, in-office solutions, Femasys aims to reduce healthcare costs while improving patient outcomes.

The company collaborates with healthcare providers, distributors, and research institutions to expand its market reach and accelerate product adoption. Femasys also invests heavily in research and development to maintain its competitive edge and address emerging needs in women’s healthcare.

Strategic Direction

Femasys is committed to driving growth through innovation and market expansion. The company’s strategic priorities include:

  • Product Development: Femasys plans to expand its product portfolio by developing new solutions for women’s health, including advanced diagnostic tools and fertility treatments.
  • Global Expansion: The company aims to increase its international presence by entering new markets and establishing partnerships with global healthcare providers.
  • Sustainability Goals: Femasys is dedicated to promoting sustainability by developing eco-friendly products and minimizing its environmental footprint.
  • Regulatory Approvals: The company is focused on obtaining regulatory approvals for its products in key markets, ensuring compliance with global standards.

Competitive Landscape

Femasys operates in a competitive market that includes both established players and emerging startups. Key competitors include:

  • CooperSurgical: A leader in women’s health products, offering a wide range of fertility and contraception solutions.
  • Hologic, Inc.: Known for its advanced diagnostic and surgical products for women’s health.
  • Boston Scientific: A global medical technology company with a strong presence in the women’s health sector.
  • Conceptus, Inc.: Specializes in permanent contraception solutions, competing directly with Femasys’ FemBloc system.

Despite the competition, Femasys differentiates itself through its focus on non-surgical, cost-effective solutions and its commitment to addressing unmet needs in women’s healthcare.

Risk Factors

Femasys faces several risks that could impact its operations and financial performance:

  • Market Dependence: The company relies heavily on the success of its core products, such as FemaSeed and FemBloc. Any decline in demand for these products could adversely affect revenue.
  • Regulatory Challenges: Obtaining and maintaining regulatory approvals is a complex and time-consuming process that could delay product launches.
  • Supply Chain Disruptions: Dependence on third-party suppliers for raw materials and components exposes Femasys to potential supply chain disruptions.
  • Competition: The presence of well-established competitors with greater resources poses a significant challenge to Femasys’ market share.

Recent Developments

Femasys has made significant strides in recent years, including:

  • Clinical Trials: The company has completed pivotal clinical trials for its FemBloc system, demonstrating its safety and efficacy.
  • Regulatory Milestones: Femasys has received FDA clearance for several of its products, paving the way for commercialization in the U.S. market.
  • Partnerships: The company has entered into strategic partnerships with leading healthcare providers to expand its distribution network.
  • Technological Innovations: Femasys continues to invest in R&D, resulting in the development of next-generation products for infertility treatment and cancer diagnostics.

Investment Considerations

Strengths

  • Innovative Product Portfolio: Femasys offers unique, non-surgical solutions that address unmet needs in women’s healthcare.
  • Strong Leadership: The company’s experienced management team provides a solid foundation for growth.
  • Market Potential: With increasing demand for cost-effective and minimally invasive healthcare solutions, Femasys is well-positioned for long-term growth.

Risks

  • Regulatory Hurdles: Delays in obtaining regulatory approvals could impact product launches and revenue.
  • Competitive Pressure: The presence of larger competitors with established market positions poses a risk to Femasys’ growth.
  • Financial Constraints: As a relatively small company, Femasys may face challenges in securing funding for R&D and market expansion.

Conclusion

Femasys Inc. is a pioneering medical technology company that is transforming women’s healthcare through innovative, non-surgical solutions. With a strong product portfolio, experienced leadership, and a commitment to addressing unmet needs, Femasys is well-positioned for growth in the rapidly evolving healthcare market. However, the company must navigate regulatory challenges, competitive pressures, and financial constraints to achieve its long-term objectives. Overall, Femasys represents a compelling investment opportunity for those seeking exposure to the women’s health sector.